Description
Neovir Pharmacodynamics
The drug has antiviral action against DNA and RNA-genomic viruses. It has a pronounced antichlamydial effect.
Neovir® causes rapid increase in titers of endogenous interferon a, p, y, especially interferon a. Intramuscular administration of 250 mg of Neovir® is equivalent to administration of 6-9 million ME of recombinant interferon a with regard to detectable serum concentrations of interferon. Peak interferon activity in blood is observed 1.5-2 hours later and persists for 16-20 hours after Neovir® administration. As a result, a cascade of immune reactions is induced in the body aimed at destruction and elimination of pathogens and affected cells. Interferon-producing cells acquire the ability to enhance production of interferon in response to re-induction caused by the pathological agent. This property is maintained for a long time after discontinuation of the drug.
The immunomodulatory activity is due to the ability of Neovir® to activate hematopoietic stem cells, to normalize the balance of T-lymphocyte subpopulations, to stimulate effector links of immune system. Neovir® has a marked stimulatory effect on the functional activity of macrophages and polymorphonuclear leukocytes, increasing their migration and phagocytic activity.
Neovir® corrects tissue growth: it activates NK cells, enhances all forms of cytotoxicity, positively affects restoration of cell adhesiveness, inhibits their proliferative and metastatic activity.
Indications
In the form of monotherapy or as part of the complex therapy:
– Influenza and other acute respiratory viral diseases, including against the background of immunodeficiency states;
– Infections caused by Herpes simplex virus, Varicella zoster, Herpes simplex genitalis, including in people with immune system disorders;
– Cytomegalovirus infection in immunodeficient persons;
– radiation immunodeficiency;
– HIV infection;
– encephalitis and encephalomyelitis of viral etiology;
– Acute and chronic hepatitis B and C;
– urethritis, epididymitis, prostatitis, cervicitis, and salpingitis of chlamydial etiology;
– venereal lymphogranuloma;
– cancer diseases;
– multiple sclerosis;
– Candida infections of skin and mucous membranes;
– Papillomavirus infection.
Prevention of influenza and other acute respiratory viral diseases.
Contraindications .
– Individual intolerance to the drug;
– Severe renal insufficiency (creatinine clearance less than 30 ml/min);
– autoimmune diseases;
– Pregnancy and lactation;
– Childhood under 18 years old.
Caution:
Use with caution in elderly patients.
Use during pregnancy and during breast-feeding:
The safety of Neovir® use in pregnancy and lactation has not been studied, so the drug is contraindicated for use in pregnancy and during breast-feeding.
Dosage and administration method
- The solution for injection is administered intramuscularly, single therapeutic dose is 250 mg (1 ampoule) or 4-6 mg per kg of body weight. If necessary, a single dose of Neovir® may be increased up to 500 mg.
- The course of treatment, if there are no special indications, consists of 5-7 intramuscular injections of Neovir® in dose of 250 mg at intervals of 48 hours; the course dose depends on clinical picture. Course duration is 8-12 days. A single prophylactic dose is 250 mg (1 ampoule) or 4-6 mg per kg body weight. During long-term use the recommended interval between Neovir® doses is 3-7 days.
- In HIV-infection Neovir® solution for injection is used in combination with specific antiviral drugs. The treatment course consists of 10 injections of 250 mg with an interval of 48 hours between injections. After the course a break of 2 months is made. It is possible to use repeated courses when indicated.
